ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 574,04
-0,77%
Dow Jones
40 211,72
0,00%
DAX
18 495,55
-0,56%
Brent Oil
82,905
-1,70%
Bitcoin
63 792,19
-1,63%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
15/02/202313h24Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/202321h33Edgar (US Regulatory)Schedule 13g
(sc 13g/a)		NYSE:TEVATeva Pharmaceutical Industries Ltd
10/02/202313h04Edgar (US Regulatory)Annual Report (10-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202315h05Dow Jones NewsTeva to Pay Florida $6.7 Million to Settle Price-Fixing AllegationsNYSE:TEVATeva Pharmaceutical Industries Ltd
09/02/202314h00Business WireTeva Reaches Agreement With Florida to Settle the State’s Price Fixing ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/202322h23Edgar (US Regulatory)Securities Registration (ads, Immediate) (f-6ef)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/202313h00Business WireTeva Reports Fourth Quarter and Full Year 2022 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
23/01/202315h35Dow Jones NewsTeva Seeks FDA OK for Generic Form of Catalyst's FirdapseNYSE:TEVATeva Pharmaceutical Industries Ltd
19/01/202313h00Business WireTeva’s Ambitious Climate Targets Externally Validated by the Science Based Targets initiative (SBTi)NYSE:TEVATeva Pharmaceutical Industries Ltd
12/01/202322h30Business WireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results and 2023 Financial Guidance at 8 a.m. ET on February 8, 2023NYSE:TEVATeva Pharmaceutical Industries Ltd
09/01/202315h13Dow Jones NewsTeva Moves Forward With Nationwide Opioid SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/01/202314h00Business WireTeva Announces Nationwide Opioids Settlement to Move Forward After Receiving Broad Support from StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/202320h21Dow Jones NewsAlvotech, Teva Shares Rise After FDA Accepts BLA for AVT04NYSE:TEVATeva Pharmaceutical Industries Ltd
06/01/202313h00Business WireAlvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/01/202322h30Business WireTeva to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/202210h00GlobeNewswire Inc.Update on U.S. Regulatory Status of AVT02, Alvotech’s Proposed High-Concentration, Interchangeable Biosimilar to Humira®NYSE:TEVATeva Pharmaceutical Industries Ltd
13/12/202219h24Dow Jones NewsVanda Pharmaceuticals Shares Tumble After Loss in Hetlioz Patent SuitNYSE:TEVATeva Pharmaceutical Industries Ltd
23/11/202208h44Dow Jones NewsTeva, Allergan Finalize Terms of Nationwide Opioid Settlement -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
22/11/202214h30Business WireTeva Finalizes Nationwide Opioid Settlement TermsNYSE:TEVATeva Pharmaceutical Industries Ltd
21/11/202213h02Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
21/11/202213h00Business WireTeva Announces Appointment of Richard Francis as President and CEONYSE:TEVATeva Pharmaceutical Industries Ltd
14/11/202214h01Business WireTeva Announces Unique Collaboration with Rimidi to Expand the Reach of its Respiratory Digital Health PlatformNYSE:TEVATeva Pharmaceutical Industries Ltd
14/11/202214h00Business WireTeva Announces Unique Collaboration with HealthSnap to Expand the Reach of its Respiratory Digital Health PlatformNYSE:TEVATeva Pharmaceutical Industries Ltd
10/11/202214h54TipRanksEli Lilly (NYSE:LLY) Loses Migraine Drug Patent Trial to TevaNYSE:TEVATeva Pharmaceutical Industries Ltd
07/11/202222h30Business WireTeva to Present Latest Research from the CONNECT1 and CONNECT2 Clinical Trials at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific MeetingNYSE:TEVATeva Pharmaceutical Industries Ltd
07/11/202217h40TipRanksAnalysts Have Conflicting Sentiments on These Healthcare Companies: Akero Therapeutics (AKRO), Immunovant (IMVT) and Teva Pharmaceutical (TEVA)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/11/202221h16Edgar (US Regulatory)Quarterly Report (10-q)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/11/202212h00Business WireTeva Reports Third Quarter 2022 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
25/10/202216h00Business WireClinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFCNYSE:TEVATeva Pharmaceutical Industries Ltd
18/10/202214h00Business WireTeva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s DiseaseNYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

BITMOT
859263
Ifc Tf 6,5% Fb26 Rub
LSE
CPP
Cppgroup
NASDAQ
CSCD
TG
0I88
iShares MSCI World ETF
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés